CureVac (CVAC) began trading on the Nasdaq on Fri 14 Aug 2020

CureVac priced 13.3 mln share IPO at $16, the high end of the $14-$16 expected price range
CureVac BV raised $213 million in its initial public offering (IPO) in New York on Thursday, setting the stage for the first stock market debut of a company developing a promising vaccine to combat the coronavirus.

• The big draw is its mRNA COVID-19 vaccine candidate, currently in Phase 1 development. Topline data should be available next quarter.
• Lead program is CV8102, also in Phase 1 development, for the treatment of four types of solid tumors.
• Earlier this year, CureVac tapped investors, including the German government and GSK, for $640M to support its work against the coronavirus and other diseases.

BioNTech (BNTX) began trading on the Nasdaq on Thur 10 Oct 19

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 1,179
• Founded in 2008
• HQ in Mainz, Germany
• http://www.biontech.de

BioNTech priced 10 mln share IPO at $15.00, the low-end of the reduced $15.00-$16.00 range

MorphoSys AG (MOR) began trading on the Nasdaq on 19 April 2018

MorphoSys AG is a German biotechnology company. It is involved in the development and research of antibodies. TecDAX has listed MorphoSys since 2004.

• Headquarters: Planegg, Germany
• Number of employees: 460 (end 2010)
• Founded: 1992, Martinsried, Germany
• morphosys.com

MorphoSys raised upwards of $207.8 million. The company says it’s gathering resources to sink $225 million into the development of its investigational anti-CD19 antibody MOR208 -- a drug it’s developing for diffuse large B cell lymphoma (DLBCL).  After its last batch of upbeat data from a Phase II study, MorphoSys, which already received breakthrough status for the drug, said it went straight to regulators hoping for early approval.

Trivago NV (TRVG) began trading on Nasdaq on 16 Dec 2016

• Trivago NV is a German hotel search and booking site
• Rivals: TripAdvisor Inc. and Priceline Group Inc.
• Spinoff from Expedia 

Trivago founder and CEO Rolf Schromgens

Voxeljet (VJET) began trading on the NYSE on 18 October 2013

Voxeljet provides three-dimensional (3D) printers and on-demand parts services.

• Revenue  $11.25M
• Net Income  $273,849
• 2012 Sales Growth  10.8%
• Employees  87

Ticker: VJET

Voxeljet Celebrates IPO at NYSE 

German technology company Voxeljet (NYSE:VJET) began trading on the NYSE today, and executives celebrated the IPO on the Trading Floor. 

 

CEO Ingo Ederer and CFO Rudolf Franz of Voxeljet visit the New York Stock Exchange to celebrate the company's IPO on October 18, 2013 in New York City.

Voxeljet produces large-format 3D printing machines and on-demand parts services, which are sold to customers in automotive, aerospace, film, entertainment, art, architecture, engineering and consumer product sectors.

In February, 3D printer maker ExOne (XONE) launched at $18 a share, closed its first day at 26.52 and was trading near 54.30 Friday afternoon, up 2.5%.

The only other publicly traded 3D printer makers have also had top-performing stocks, as the manufacturing technology is fast gaining steam in business and even consumer markets. The largest, 3D Systems (DDD), was up 1% near 57, and is up more than 60% for the year. Stratasys (SSYS) stock was up 2% near 112, and it's up 40% in 2013.

In its IPO filings, Voxeljet said it has a global installed base of 52 printers. It said 2012 revenue rose 20% to 8.7 million euros, or $11.3 million. It said profit rose 393% to 212,000 euros, or $276,000.

In the first six months of the year ended June 30, Voxeljet reported revenue of 4.4 million euros ($5.8 million), down 3.5% from the year-earlier period. In that span, it said it swung to a loss of 376,000 euros ($489,000) from a profit of 319,000 euros.

Voxeljet plans to use the funds from the offering to expand its on-demand parts service center in Europe and build new on-demand parts service centers in North America and Asia. The company also expects to boost its R&D and marketing efforts and set some of the cash aside for acquisitions.